- Research article
- Open Access
- Open Peer Review
Dickkopf-4 is frequently overexpressed in epithelial ovarian carcinoma and promotes tumor invasion
BMC Cancervolume 17, Article number: 455 (2017)
Dickkopf-4 (DKK4), a member of DKK family, appears to be a divergent protein. It remained multi-biological functions in carcinogenesis. The effect of DKK4 on the ovarian cancer cells remains unclear. This study detected the clinical significance of DKK4 in epithelial ovarian cancer (EOC) patients and its role in invasion.
QRT-PCR and western blot analysis were used to examine the levels of DKK4 mRNA and protein in 33 EOC tissues and 33 benign ovarian tumors. Immunohistochemical analysis was performed to assess DKK4 expression in 239 EOC samples. siRNA-mediated DKK4 silence was conducted. Transwell assay was used to detect the invasive ability. Phalloidin was used to stain the formations of actin filaments.
The expressions of DKK4 mRNA and protein were elevated in EOC tissues as compared with those in benign ovarian tumors (p = 0.001 and <0.0001 respectively). Immunohistochemical results showed the strong expression of DKK4 protein was positively associated with late FIGO stage (p = 0.005) and poor disease free survival in univariate and multivariate analysis (p < 0.0001 and p = 0.001, respectively). SiRNA-mediated DKK4 knockdown inhibited cell invasive ability (all p < 0.0001) and the formations of actin filaments. DKK4 could promote the phosphration of c-JUN and JNK (p < 0.0001 and p = 0.001, respectively).
Our results indicated that DKK4 might be contributed to predicting EOC progression and prognosis. DKK4 could promote the invasion of EOC through JNK activation.
Epithelial ovarian carcinoma is one of most common ovarian cancers. Its mechanism is unclear . Its diagnosis and prognosis was late and poor due to its delayed symptoms and insensitive biomarkers [2, 3]. Consequently, it’s necessary for us to detect protein marker for predicting epithelial ovarian carcinoma progression and prognosis. The DKK family encodes secreted proteins in vertebrates (DKK1 to 4) [4,5,6]. DKK4 was one of DKK family member, it firstly acted as antagonist of Wnt proteins through binding to lipoprotein receptor-related protein 5/6 (LRP5/6), which induced the binding complex endocytosis and inhibiting Wnt/β-catenin activation [7,8,9,10]. Recently, DKK4 was found to be involved in carcinogenesis. Its functional role in tumor carcinogenesis was complicated. The earlier studies suggested that DKK4 was down-regulated in human tumors, for example in hepatocellular carcinoma and colorectal cancer, which indicated that DKK4 might act as a tumor suppressor by inhibiting Wnt/β-catenin signaling [11,12,13,14]. However, DKK4, induced by β-catenin activation, was found to be upregulated and promote invasion and angiogenesis in human colon cancers [15, 16]. DKK4 was co-overexpressed with MAPK3 and VAV3 in pancreatic ductal adenocarcinoma tissues . DKK4 could also promote cell proliferation, invasion, and migration by activating the noncanonical c-Jun-NH2 kinase signaling pathway in renal cancer . These studies suggest that DKK4 appears to be a divergent member of the DKK family, which remained multi-biological functions in carcinogenesis.
Till now, the expression and role of DKK4 in cancer invasion especially in epithelial ovarian cancer remained unclear. In the present study, we investigated the expression of DKK4 in epithelial ovarian carcinoma to prove the correlation between DKK4 with clinical parameters of EOC. Then we investigated its role in predicting EOC prognosis, regulating cancer cell invasion and its mechanism in regulating c-jun pathway.
Frozen primary EOC tissues (n = 33), benign epithelial ovarian tumors (n = 33) and archival paraffin-embedded EOC samples (n = 239) were obtained from patients with primary epithelial ovarian tumors, aged 28 to 64 years, at Shengjing Hospital (Shenyang, China), from May 2009 to April 2014. Samples were selected for the study based on the criteria and followed up as previously reported . After surgical treatment, the 239 ovarian carcinoma patients, whose archival paraffin-embedded samples were selected for immunohistochemical analysis, were followed up from May 1, 2009 to April 30, 2014. These 239 ovarian carcinoma patients were followed from the date of first resection surgery to the date of ovarian cancer recurrence or last observation. 99 patients were recurrent, 53 patients were lost to follow-up, and 87 patients were alive. Ethical approval for human subjects was obtained from the research ethics committee of ShengJing Hospital. Informed consent was obtained from patients enrolled in this study.
Quantitative real-time RT-PCR
Tissue RNA and cell RNA, extracted from frozen paired tissues, were reverse transcribed using a TaKaRa RNA PCR kit. Quantitative real-time PCR was performed using the real-time PCR system 7300 (Applied Biosystems). PCRs were performed in triplicate. The relative levels of mRNA were analyzed by the 2 − ΔΔCt method. ΔCt = Ct (target)-Ct(β-actin). The mean expression level of DKK4 in normal tissues was used as control and considered as a value of 1.0, as described by Jarboe . Using the following primers:
Tissue protein was extracted from frozen tissues and cells protein was lased with sodium dodecyl sulfate buffer. Proteins were extracted with RIPA buffer. Proteins with same concentration were separated on a 10% SDS-PAGE and then transferred to PVDF membranes. The membranes were blocked with 3% BSA in Tris-buffered saline with tween (TBST) and incubated with primary antibody DKK4 (1:500, R&D), anti-c-jun (1:400) (Abcam), anti-p-c-jun (1:350) (Santa Cruz), anti-JNK1/2 (1:400) (Abcam), anti-p-JNK (1:500) (Santa Cruz) followed by incubation with secondary antibody. Protein expression was visualized using enhanced chemiluminescence. Comparison between different groups were made by determining the specific protein/β-actin ratio of the immunoreactive area with densitometry. The tests were performed in triplicate.
Samples were fixed by formalin, embedded in paraffin and cut into sections (4–6 μm thick). Then the sections were deparaffnized, and stained using a streptavidin-biotin immunoperoxidase technique. The nucleus was stained with hematoxylin. DKK4 antibody (Abcam) was diluted as 1:250. Staining was scored as negative, weak, or strong, and rated by by multiplication of the intensity and positivity scores. (intensity: no staining, score 0; light yellow staining, score 1; moderate yellow staining, score 2; strong yellow staining, score 3; percentage < 5%, score 0; between 5% and 25%, score 1; between 26% and 50%, score 2; between 51% and 75%, score 3; >75%, score 4). Scores of 9–12 were considered as “strong”, scores of 5–8 were considered as “weak”, and scores of 0–4 were considered as “negative”, as mentioned by Hao et al. . All of the stained sections were reviewed by two independent pathologists.
siRNA transfection for DKK4 silence in vitro
37.5 × 104 (6-well) HO-8910 and SKOV-3 cells were incubated in RPMI 1640 medium without antibiotics. After 12 h, 100 nmol/L (6-well) siRNA oligonucleotides was transfected using lipofectamine™ 2000 transfection reagent (Invitrogen). siRNA were designed: DKK4-specific siRNA (sense 5′-AGGAAGCAGAGA AACCCGGC-3′). Control cells were transfected with control siRNA.
Transwell invasion assay
The transwell migration (Corning, USA) was performed using a chamber system with matrigel gel membrane (8.0 lm pore) from BD system (BD, USA). The 2 × 104 cells were incubated into a 24-well plate with the upper chamber with 1% FBS medium, and the bottom was covered with the medium containing 20% FBS and 10 μg/ml of bovine fibronectin (chemoattractant) (Hyclone). The cells, migrated for 24 h, were fixed and counted in 10 high-powered (×200) fields under a microscope. The experiment was repeated three times.
Drugs and reagents
To detect the ability of JNK on ovarian cancer cell invasion. 4 × 105 cells were pretreated with the JNK inhibitor SP600125 (0, 5 or 10 μM) in RPMI 1640 medium containing 5% FBS for 30 min before being added to the Matrigel-coated Transwell inserts. The cells, migrated for 12 h, were fixed and counted in 10 high-powered (×200) fields under a microscope as mentioned by Gonzalez-Villasana V et al. . The experiment was repeated three times.
Filamentous actin staining
Cells were washed with PBS (pH 7.4), fixed in methanol, rinsed and permeabilized with PBS containing 0.1% Triton X-100. Fixed cells were blocked for 1 h in 3% BSA and incubated with FITC-phalloidin (Sigma) for 30 min and then washed with PBS. The DNA dye DAPI (Molecular Probes) was used as nuclear stain. Images were obtained using a Laser confocal microscopy in 5 high-powered (×1000) fields. Multiple cells were categorized in each experimental point.
Results from DKK4 expression, invasion ability, c-jun protein and JNK protein were evaluated by t-test. The Pearson chi-square and Fisher exact tests were used to examine DKK4 protein expression and its correlation with clinicopathological parameters. DFS was defined as the time from the date of first resection surgery to the date of ovarian cancer recurrence. Kaplan-Meier analysis was used for predicting DFS, assessed by the log-rank test. Hazard ratios and corresponding 95% confidence intervals were determined by Cox Regression model. Estimates of effect were estimated in models that included additional adjustment for clinical predictors, including DKK4, FIGO stage, age, cell differentiation, and lymph node metastasis. All statistical analyses were performed using SPSS 13.0. Statistical significance was defined as p < 0.05.
DKK4 mRNA and protein were over-expressed in ovarian cancer
We compared the expression of DKK4 mRNA and protein in human EOC tissues and benign ovarian tumor tissues by qRT-PCR and western bolt. We found that the relative fold of DKK4 mRNA was significantly increased in EOC tissues (3.63 ± 2.84) than that in benign ovarian tumor tissues (1.66 ± 1.36) (p = 0.001; Fig. 1a). The relative level of DKK4 protein was significantly upregulated in EOC tissues (0.86 ± 0.01) than that in benign ovarian tumor tissues (0.37 ± 0.03) (p < 0.0001; Fig. 1b and c).
The prognostic significance of DKK4 protein in epithelial ovarian patients
The result of immunohistochemistry analysis showed that DKK4 was positively expressed in epithelial ovarian cancer samples. DKK4 was strong expressed in 148/239 ovarian cancer samples, weak expressed in 72/239 ovarian cancer samples, while negative expressed in only 19/239 ovarian cancer samples. Meanwhile the strong expression of DKK4 protein in ovarian cancer samples was positively correlated with late FIGO stage with p = 0.005 (Fig. 2a, Table 1). The strong expression of DKK4 protein were not associated with age, cell differentiation or lymphatic metastasis in patients with epithelial ovarian cancer (all p > 0.05) (Table 1).
The mean ± SD of the mean disease-free survival time for the entire group of 239 patients was 43.45 ± 1.18 (95% CI = 41.14–45.77) months. The mean disease-free survival time for patients with strong expression of DKK4 (38.32 ± 1.33 (95% CI = 35.73–40.92) months) was significantly lower as compared with that with weak or negative DKK4 expression (49.15 ± 1.67 (95% CI = 45.88–52.42) months, (p < 0.0001, log-rank test)) (Fig. 2b). The mean disease-free survival time for patients with late FIGO stage (37.78 ± 1.43 (95% CI = 34.97–40.58) months) was significantly lower as compared with that with early FIGO stage (48.70 ± 1.59 (95% CI = 45.58–51.82) months, (p < 0.0001, log-rank test)) (Fig. 2c). Unadjusted Cox regression revealed DKK4 level (HR = 2.10, 95% CI = 1.33–3.33, P = 0.001) and FIGO stage (HR = 2.18, 95% CI = 1.41–3.37, P < 0.0001) were independent disease-free prognostic factors for epithelial ovarian carcinoma patients. This association ((DKK4 level (HR = 2.18, 95% CI = 1.37–3.46, P = 0.001) and FIGO stage (HR = 2.21, 95% CI = 1.41–3.46, P = 0.001)) was also significant in the multivariate Cox model adjusted for age, cell differentiation, and lymph node metastasis. However, age (HR = 0.75, 95% CI = 0.50–1.13, P = 0.170), cell differentiation (HR = 0.80, 95% CI = 0.54–1.20, P = 0.29), and lymph node metastasis (HR = 1.25, 95% CI = 0.82–1.91, P = 0.30) were not significantly correlated with disease-free survival rates.
DKK4 could promote ovarian cancer cell invasion
DKK4 siRNA plasmid was transfected into SKOV-3 and HO-8910 cells lines, respectively. The knockdown efficiency of DKK4 protein in both SKOV-3 and HO-8910 cells were also confirmed by western blot (all p < 0.0001) (Fig. 3a and b). We detected the effect of DKK4 siRNA on ovarian cancer cell invasion (control siRNA vs. DKK4 siRNA) and the invasion ability of normal SKOV-3 and HO-8910 cells. Our results showed that DKK4 knockdown significantly decreased the incidence of invasion in ovarian cancer cells (SKOV-3: control siRNA (177.97 ± 29.59) vs. DKK4 siRNA (49.43 ± 23.57), p < 0.0001; HO-8910: control siRNA (167.63 ± 11.91) vs. DKK4 siRNA (53.23 ± 4.41), p < 0.0001) (Fig. 3c and d).
DKK4 could promote the activity of JNK
Previous studies found that the activation of JNK pathway could promote ovarian cancers progression [23, 24]. We detected the expression of JNK and c-JUN protein in 10 ovarian cancer tissues and 10 benign ovarian tumors. Our results showed that the levels of JNK and c-JUN protein in cancer tissues were both strong (Fig. 4a). Our results are consistent with previous studies [25, 26]. Then, we detected the activity of JNK and c-JUN in DKK4 siRNA cells. Our results showed that the phosphration of c-jun in DKK4 siRNA group was significantly decreased as compared with those in control siRNA group (DKK4- siRNA SKOV-3 group vs. control siRNA group, p = 0.001; DKK4- siRNA HO-8910 group vs. control siRNA group,p < 0.0001) (Fig. 4b and d). The phosphration of JNK in DKK4- siRNA group was significantly decreased as compared with those in siRNA control group (DKK4- siRNA SKOV-3 group vs. control siRNA group, p < 0.0001; DKK4- siRNA HO-8910 group vs. control siRNA group, p < 0.0001) (Fig. 4c and d). The band intensity of p-c-JUN or p-JNK was normalized to each corresponding band of c-JUN or JNK, respectively. The results indicated that DKK4 could promote JNK activation. Meanwhile, the inhibition of JNK activity, blocked by JNK specific inhibitor (SP600125), could decrease the invasive ability of ovarian cancer cells (SP600125 10 μM SKOV-3 group (42.43 ± 3.23) vs. control group (180.63 ± 9.67), p < 0.0001; SP600125 5 μM SKOV-3 group (70.97 ± 3.40) vs. control group (180.63 ± 9.67), p < 0.0001; SP600125 10 μM HO-8910 group (42.57 ± 3.56) vs. control group (179.83 ± 11.03), p < 0.0001;SP600125 5 μM HO-8910 group (71.17 ± 5.82) vs. control group (179.83 ± 11.03), p < 0.0001) (Fig. 4f and g). These results indicated that DKK4 could promote ovarian cancer cell invasion through promoting JNK activation.
DKK4 could promote the formations of actin filaments
Many evidence indicated that actin filaments played an important role in promoting cell invasion [27, 28]. The activation of JNK pathway was known to be involved in modulating cytoskeleton like actin filaments [29, 30]. We examined the formation of actin by using phalloidin staining. Our results found that the majority of DKK4 silenced cells lost their actin filaments as compared with that in control siRNA groups (Fig. 5).
To date, DKK4 is the least studied and characterized member of the DKK family. DKK4 firstly, could act as a tumor suppressor by inhibiting the Wnt pathway [11,12,13,14]. However, DKK4 was later found that upregulated in human cancer, promoted tumor cell invasion and angiogenesis [15,16,17,18]. These results suggested that the role DKK4 in tumorigenesis was complex.
Till now, the expression pattern and mechanism of DKK4 in cancer was still obscure. In this study, our data supported a new role for DKK4 in human epithelial ovarian cancer. We for the first time investigated the expression of DKK4 and its function in EOCs. Our present results showed that DKK4 was upregulated at both the transcriptional and translational levels in EOCs. Immunohistochemistry analysis found that high DKK4 protein was associated with late FIGO stage, suggesting that DKK4 might be involved in EOC progression. A larger number of samples needed to be analyzed to testify our results. Although DKK4 overexpression was found in some cancers, like, colon [15, 16, 31], pancreatic , and renal cancer , limited information was available on the role of DKK4 protein in predicting cancer prognosis. In this report, our results showed that elevated DKK4 protein expression was correlated with poor prognosis for EOC patients. Meanwhile, DKK4 and FIGO stage were the independent predictors for EOC prognosis. Meanwhile, our in vitro assay also showed that DKK4 could promote EOC cell invasion.
The reason why DKK4 overexpression predicted poor prognosis for ovarian cancer patients and promoted invaion was unclear. Recently, Hirata H et al. also found that DKK4 could activate JNK pathway while inhibiting β-catenin signaling in renal cell carcinoma . Ouyang et al. found that DKK4 might promote the development of pancreatic cancer through the abnormal activation of MAPK3 pathway . In this report, our results found that DKK4 could promote c-jun and JNK protein phosphration, indicating DKK4 could promote invasion through activating JNK pathway. We also examine the expression of β-catenin and MAPK3 phosphration in DKK4 siRNA silenced cells, however, DKK4 failed to changed β-catenin or MAPK3 pathway (data not shown). The mechanism of DKK4 in activating JNK pathway was unclear. Hisham Bazzi et al. considered DKK4 overexpression as the constituted activation of Wnt/β-catenin signaling pathway [32, 33]. Wnt/β-catenin signaling pathway was activated in ovarian cancer progression . Taken together, we hypothesized that DKK4 might be considered as a switch, shifting Wnt canonical to JNK signaling pathway. Large more studies were needed to testify the role of DKK4 in signal pathway activation.
The formation of actin filaments was one of the most important steps in promoting cell invasion . The activation of JNK pathway was known to be involved in modulating cytoskeleton like actin filaments [36, 37]. Our results showed that DKK4 might promote the formations of actin filaments through activating JNK pathway. However, more studies also should be conducted to prove it.
The present study observed that DKK4 mRNA and protein were elevated in EOC tissues. Immunohistochemical results showed the strong expression of DKK4 protein was positively associated with late FIGO stage and poor disease free survival time. SiRNA-mediated DKK4 knockdown inhibited cell invasive ability and the formations of actin filaments. DKK4 could promote the phosphration of c-JUN and JNK. In sum, we have shown that DKK4 was over-expressed, predicated poor prognosis and promoted tumor invasion through acitvating JNK in EOC carcinogenensis.
c-Jun N-terminal kinase
epithelial ovarian cancer
- MAP K3:
Mitogen-activated protein kinase 3
phosphrated c-Jun N-terminal kinase
T cell factor
Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology. 2001;38:87–95.
Lim D, Oliva E. Precursors and pathogenesis of ovarian carcinoma. Pathology. 2013;45(3):229–42.
Salamanca CM, Maines-Bandiera SL, Leung PC, Hu YL, Auersperg N. Effects of epidermal growth factor/hydrocortisone on the growth and differentiation of human ovarian surface epithelium. J Soc Gynecol Investig. 2004;11:241–51.
Hsieh JC, Kodjabachian L, Rebbert ML, Rattner A, Smallwood PM, Samos CH, Nusse R, Dawid IB, Nathans J. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature. 1999;398(6726):431–6.
Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci. 2003;116:2627–34.
Roth W, Wild-Bode C, Platten M, Grimmel C, Melkonyan HS, Dichgans J, et al. Secreted frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. Oncogene. 2000;19:4210–20.
Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene. 2006;25:7469–81.
Sato H, Suzuki H, Toyota M, Nojima M, Maruyama R, Sasaki S, et al. Frequent epigenetic inactivation of DICKKOPF family genes in human gastrointestinal tumors. Carcinogenesis. 2007;28:2459–66.
Hiramitsu S, Terauchi M, Kubota T. The effects of Dickkopf-4 on the proliferation, differentiation, and apoptosis of osteoblasts. Endocrinology. 2013;154(12):4618–26.
Sima J, Piao Y, Chen Y, Schlessinger D. Molecular dynamics of Dkk4 modulates Wnt action and regulates meibomian gland development. Development. 2016;143(24):4723–35.
Fatima S, Lee NP, Tsang FH, Kolligs FT, Ng IO, Poon RT, et al. Dickkopf 4 (DKK4) acts on Wnt/β-catenin pathway by influencing β-catenin in hepatocellular carcinoma. Oncogene. 2012;31:4233–44.
Baehs S, Herbst A, Thieme SE, Perschl C, Behrens A, Scheel S, et al. Dickkopf-4 is frequently down-regulated and inhibits growth of colorectal cancer cells. Cancer Lett. 2009;276:152–9.
Liao CH, Yeh CT, Huang YH, Wu SM, Chi HC, Tsai MM, et al. Dickkopf 4 positively regulated by the thyroid hormone receptor suppresses cell invasion in human hepatoma cells. Hepatology. 2012;55:910–20.
Sato H, Suzuki H, Toyota M, et al. Frequent epigenetic inactivation of DICKKOPF family genes in human gastrointestinal tumors. Carcinogenesis. 2007;28:2459–66.
Matsui A, Yamaguchi T, Maekawa S, Miyazaki C, Takano S, Uetake T, et al. DICKKOPF-4 and -2 genes are upregulated in human colorectal cancer. Cancer Sci. 2009;100:1923–30.
Pendas-Franco N, Garcia JM, Pena C, et al. DICKKOPF-4 is induced by TCF/beta-catenin and upregulated in human colon cancer, promotes tumour cell invasion and angiogenesis and is repressed by 1alpha, 25-dihydroxyvitamin D3. Oncogene. 2008;27:4467–77.
Ouyang Y, Pan J, Tai Q, Ju J, Wang H. Transcriptomic changes associated with DKK4 overexpression in pancreatic cancer cells detected by RNA-Seq. Tumour Biol. 2016;37(8):10827–38.
Hirata H, Hinoda Y, Majid S, Chen Y, Zaman MS, Ueno K, et al. DICKKOPF-4 activates the noncanonical c-Jun-NH2 kinase signaling pathway while inhibiting the Wnt-canonical pathway in human renal cell carcinoma. Cancer. 2011;117:1649–60.
Shizhuo W, Tao J, Shulan Z, Bing Z. The expression and significance of Dickkopf-1 in epithelial ovarian carcinoma. Int J Biol Markers. 2009;24:165–70.
Jarboe JS, Johnson KR, Choi Y, Lonser RR, Park JK. Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies. Cancer Res. 2007;67:7983–6.
Hao XP, Pretlow TG, Rao JS, Pretlow TP. Beta-catenin expression is altered in human colonic aberrant crypt foci. Cancer Res. 2001;61:8085–8.
Gonzalez-Villasana V, Gutiérrez-Puente Y, Tari AM. Cyclooxygenase-2 utilizes Jun N-terminal kinases to induce invasion, but not tamoxifen resistance, in MCF-7 breast cancer cells. Oncol Rep. 2013;30(3):1506–10.
Vivas-Mejia P, Benito JM, Fernandez A, Han HD, Mangala L, Rodriguez-Aguayo C, et al. C-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res. 2010;16(1):184–94.
Liu H, Liang SL, Kumar S, Weyman CM, Liu W, Zhou A. Statins induce apoptosis in ovarian cancer cells through activation of JNK and enhancement of Bim expression. Cancer Chemother Pharmacol. 2009;63(6):997–1005.
Davidson B, Givant-Horwitz V, Lazarovici P, Risberg B, Nesland JM, Trope CG, Schaefer E, Reich R. Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma. Clin Exp Metastasis. 2003;20(7):621–31.
Ødegaard E, Staff AC, Abeler VM, Kopolovic J, Onsrud M, Lazarovici P, Davidson B. The activated nerve growth factor receptor p-TrkA is selectively expressed in advanced-stage ovarian carcinoma. Hum Pathol. 2007;38(1):140–6.
Dingemans KP. What's new in the ultrastructure of tumor invasion in vivo? Pathol Res Pract. 1988;183:792–808.
Edwards BS, Dang AK, Murtazina DA, Dozier MG, Whitesell JD, Khan SA, et al. Dynamin is required for GnRH signaling to L-type calcium channels and activation of ERK. Endocrinology. 2016;157:831–43.
Zhou H, Zhang Y, Chen Q, Lin Y. AKT and JNK signaling pathways increase the metastatic potential of colorectal cancer cells by altering Transgelin expression. Dig Dis Sci. 2016;61:1091–7.
Xia Y, Karin M. The control of cell motility and epithelial morphogenesis by Jun kinases. Trends Cell Biol. 2004;14:94–101.
Zhai W, Hu GH, Zheng JH, Peng B, Liu M, Huang JH, et al. High expression of the secreted protein dickkopf homolog 4: roles in invasion and metastasis of renal cell carcinoma and its association with von Hippel-Lindau gene. Int J Mol Med. 2014;33:1319–26.
Bazzi H, Fantauzzo KA, Richardson GD, Jahoda CA, Christiano AM. The Wnt inhibitor, Dickkopf 4, is induced by canonical Wnt signaling during ectodermal appendage morphogenesis. Dev Biol. 2007;305:498–507.
Diep DB, Hoen N, Backman M, Machon O, Krauss S. Characterisation of the Wnt antagonists and their response to conditionally activated Wnt signalling in the developing mouse forebrain. Brain Res Dev Brain Res. 2004;153:261–70.
Rask K, Nilsson A, Brännström M, Carlsson P, Hellberg P, Janson PO, et al. Wnt-signalling pathway in ovarian epithelial tumours: increased expression of Beta-catenin and GSK3beta. Br J Cancer. 2003;89:1298–04.
Korb T, Schlüter K, Enns A, Spiegel HU, Senninger N, Nicolson GL, et al. Integrity of actin fibers and microtubules influences metastatic tumor cell adhesion. Exp Cell Res. 2004;299:236–47.
Wang S, Zhang S. Dickkopf-1 is frequently overexpressed in ovarian serous carcinoma and involved in tumor invasion. Clin Exp Metastasis. 2011;28:581–91.
Xia Y, Karin M. The control of cell motility and epithelial morphogenesis by Jun kinases. Trends Cell Biol. 2004;14(2):94–101.
The study is investigator initiated and sponsored study. The investigators are solely responsible for the study. This study was supported by National Natural Science Foundation of China (No. 81302272) and Freedom Researchers Projects Shengjing Hospital (No.201302). The funding parties have no influence on study design, data collection, analysis, or interpretation.
Availability of data and materials
All data of this study are available from the corresponding author upon reasonable request.
SZW and SLZ detected the study and drafted the manuscript. SW analyzed the data and performed data analysis. SZW, SZ and HW were involved in revising the manuscript and providing critical reviews. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
Ethical approval for human subjects was obtained from the research ethics committee of ShengJing Hospital (approved No.2013PS48K). Written informed consent was obtained by all patients.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.